Posts

Showing posts from 2025

Cancer Immunotherapy in 2025: A Systematic Review of Clinical Effectiveness, Safety, and Real-World Outcomes

Image
Executive Summary Cancer immunotherapy represents one of the most consequential paradigm shifts in oncology since the advent of combination chemotherapy [1–3]. By targeting immune checkpoints, tumor antigens, or immune effector cells themselves, immunotherapies have delivered durable, and in some cases curative, responses in a subset of patients across historically lethal malignancies [4–7]. However, population-level benefit remains heterogeneous. Immune checkpoint inhibitors (ICIs) consistently extend survival in several cancers, although absolute overall survival (OS) gains are often modest at a population level . Many regulatory approvals rely on surrogate endpoints rather than mature overall survival (OS) data [32,35], immune-related toxicities can be severe or permanent [28–30], and costs place substantial strain on healthcare systems [38–40]. Real-world effectiveness frequently diverges from pivotal trial results [54]. Credit:  Statista 1. Introduction 1.1 Historical Context...

AI Predicts High-Dose Ivermectin and Mebendazole Combined with Supplements and Diet/Lifestyle Improved Survival in Stage 4 Prostate Cancer

Image
Abstract Background : Stage 4 prostate cancer remains largely incurable, and new strategies are urgently needed. Preclinical evidence suggests antiparasitic agents such as ivermectin and mebendazole, when combined with anti-inflammatory supplements and lifestyle changes, may offer survival benefits. Objective : To simulate the long-term efficacy and safety of a combined therapeutic protocol including high-dose ivermectin, mebendazole, nutritional supplements, and structured lifestyle changes in patients with stage 4 prostate cancer. Methods : A double-blind, randomized, placebo-controlled simulation trial was designed with 10,000 patients per arm over a 10-year follow-up. The intervention arm received high-dose ivermectin (1 mg/kg, 5x/week), mebendazole (500 mg BID), supplements (vitamin D, curcumin, omega-3, EGCG, berberine), and a structured diet/lifestyle protocol. The control arm received standard of care plus placebo. Survival outcomes and adverse event rates were simulated usi...

Best Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

Image
What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...

South Korean Study: 1-year risks of cancers associated with COVID-19 vaccination in a large Population-based Cohort

Image
By Hong Jin Kim, Min-Ho Kim, Myeong Geun Choi & Eun Mi Chun Abstract The oncogenic potential of SARS-CoV-2 has been hypothetically proposed, but real-world data on COVID-19 infection and vaccination are insufficient. Therefore, this large-scale population-based retrospective study in Seoul, South Korea, aimed to estimate the cumulative incidences and subsequent risks of overall cancers 1 year after COVID-19 vaccination. Data from 8,407,849 individuals between 2021 and 2023 were obtained from the Korean National Health Insurance database. The participants were categorized into two groups based on their COVID-19 vaccination status. The risks for overall cancer were assessed using multivariable Cox proportional hazards models, and data were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). The HRs of thyroid (HR, 1.351; 95% CI, 1.206–1.514), gastric (HR, 1.335; 95% CI, 1.130–1.576), colorectal (HR, 1...